Skip to search boxSkip to navigationSkip to main content

Baseline Predictors of Longitudinal Changes in Symptom Severity and Quality of Life in Patients With Suspected Gastroparesis

  • Allen A. Lee(corresponding author)
    ,
  • Krishna Rao
    ,
  • Henry P. Parkman
    ,
  • Richard W. McCallum
    ,
  • Irene Sarosiek
    ,
  • Linda A. Nguyen
*Corresponding author for this work
  • University of Vermont
    ,
  • University of Michigan, Ann Arbor
    ,
  • Temple University
    ,
  • Texas Tech University Health Sciences Center El Paso
    ,
  • Stanford University
    ,
  • Indiana University-Purdue University Indianapolis
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Background & Aims: Whether gastric emptying tests predict longitudinal outcomes in patients with symptoms of gastroparesis is unclear. We aimed to determine whether baseline gastric emptying tests and gut motility parameters could impact longitudinal symptom(s) and quality of life (QOL) in a prospective, observational cohort study of patients with symptoms of gastroparesis. Methods: One hundred fifty patients with gastroparesis symptoms underwent simultaneous scintigraphy (GES) and wireless motility capsule (WMC) measurement of gastric emptying and other motility parameters. Patient Assessment of Upper Gastrointestinal Symptoms and Quality of Life were administered at baseline, and 3 and 6 months after testing. Multivariable generalized linear marginal models were fit to determine which baseline parameters predict longitudinal changes in symptoms and QOL. Results: Overall upper GI symptoms and QOL scores were moderate in severity at baseline and significantly improved over 6 months. Clinical variables, including female gender, harder stools by Bristol stool form score, and presence of functional dyspepsia (FD) by Rome III criteria, were predictive of more severe upper GI symptoms. Even after controlling for these clinical factors, delayed gastric emptying by GES or WMC was associated with worse symptom severity and QOL scores. Low gastric and elevated small bowel contractile parameters by WMC were also independently associated with more severe upper GI symptoms and worse QOL scores. Conclusions: Baseline features, including demographic and clinical variables, delayed gastric emptying and abnormal gastrointestinal contractility, were independent predictors of more severe longitudinal symptoms and worse quality of life outcomes. These factors may help to risk stratify patients and guide treatment decisions. ClinicalTrials.gov no: NCT02022826.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages e407-e428

Journal (Volume, Issue Number)

Clinical Gastroenterology and Hepatology (Volume 20, Issue 3)

Publication milestones

  • Accepted/In press - 2021
  • Published - 03/2022

Publication status

Published - 03/2022

ISSN

1542-3565

Publication IDs

  • Scopus: 85099574597
  • PubMed: 32971231

Publication metrics

Metrics

SciVal
Author count
12
SciVal
Paper percentile
80
Fractional count
1
Fractional count
0.08
Fractional count
11
Fractional count
0.92
Fractional count
1
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
10
Captures
26
Mentions
1

Funding Details

The authors thank Dr Richard Krause for his assistance with recruiting subjects for this study. Allen Lee, MD (Data curation: Equal; Formal analysis: Lead; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Lead), Krishna Rao, MD, MS (Formal analysis: Supporting; Methodology: Equal; Writing – review & editing: Equal), Henry Parkman, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Richard McCallum, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Irene Sarosiek, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Linda Nguyen, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), John Wo, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Michael Schulman, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Baharak Moshiree, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Satish Rao, MD (Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – review & editing: Equal), Braden Kuo, MD, MS (Conceptualization: Equal; Data curation: Equal; Formal analysis: Supporting; Funding acquisition: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – original draft: Supporting; Writing – review & editing: Equal), William Hasler, MD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Supporting; Funding acquisition: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Equal; Supervision: Equal; Writing – original draft: Equal; Writing – review & editing: Equal) Conflicts of interest These authors disclose the following: AL, HP, RM, LN, JW, MS, BM, SR, BK, and WH received funding from Covidien to conduct this study. BK is a consultant for Gelesis, Ironwood Pharmaceuticals, Takeda, Alpha Waserman, Neurogastrx, Arena Pharmaceuticals, and CinRx Pharma and received research support from Vanda, Genzyme, and Covidien. The remaining authors disclose no conflicts. Funding The parent study supporting the data and analyses included in this article was funded by Covidien. Covidien did not participate in study design, data interpretation, writing support, or other preparation assistance for this article. Grant support was also provided by the NIH grants KL2TR002241 (to AL) and AI124255 (to KR). Funding The parent study supporting the data and analyses included in this article was funded by Covidien. Covidien did not participate in study design, data interpretation, writing support, or other preparation assistance for this article. Grant support was also provided by the NIH grants KL2TR002241 (to AL) and AI124255 (to KR).
FundersFunding numbers
CinRx Pharma
-
Richard McCallum
-
William Hasler
-
Baharak Moshiree
-
Satish Rao
-
NIH
-
Covidien
-
NCATS
KL2TR002241
NIAID
U01AI124255
NIDDK
K23DK124567